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A B S T R A C T
While many orthosteric ligands have been developed for the mGlu2 receptor, little is known about their target
binding kinetics and how these relate to those of the endogenous agonist glutamate. Here, the kinetic rate
constants, i.e. kon and koﬀ, of glutamate were determined for the ﬁrst time followed by those of the synthetic
agonist LY354740 and antagonist LY341495. To increase the understanding of the binding mechanism and
impact of allosteric modulation thereon, kinetic experiments were repeated in the presence of allosteric mod-
ulators. Functional assays were performed to further study the interplay between the orthosteric and allosteric
binding sites, including an impedance-based morphology assay.
We found that dissociation rate constants of orthosteric mGlu2 ligands were all within a small 6-fold range,
whereas association rate constants were ranging over more than three orders of magnitude and correlated to
both aﬃnity and potency. The latter showed that target engagement of orthosteric mGlu2 ligands is kon-driven in
vitro. Moreover, only the oﬀ-rates of the two agonists were decreased by a positive allosteric modulator (PAM),
thereby increasing their aﬃnity. Interestingly, a PAM increased the duration of a glutamate-induced cellular
response. A negative allosteric modulator (NAM) increased both on- and oﬀ-rate of glutamate without changing
its aﬃnity, while it did not aﬀect these parameters for LY354740, indicating probe-dependency.
In conclusion, we found that aﬃnity- or potency-based orthosteric ligand optimization primarily results in
ligands with high kon values. Moreover, positive allosteric modulators alter the binding kinetics of orthosteric
agonists mainly by decreasing koﬀ, which we were able to correlate to a lengthened cellular response. Together,
this study shows the importance of studying binding kinetics in early drug discovery, as this may provide im-
portant insights towards improved eﬃcacy in vivo.
1. Introduction
Glutamate is the most important excitatory neurotransmitter in the
central nervous system where it modulates synaptic responses via ac-
tivation of ionotropic glutamate receptors and metabotropic glutamate
(mGlu) receptors [1]. mGlu receptors are class C G protein-coupled
receptors (GPCRs) that structurally consist of a large extracellular glu-
tamate binding domain, the so-called Venus Flytrap (VFT) domain,
which is connected via a cysteine-rich domain to the typical seven-
transmembrane (7TM) domain [2]. The mGlu2 receptor, which is ex-
pressed presynaptically in the periphery of the synapse, is of interest in
drug discovery as it negatively modulates the release of glutamate into
the synapse [3]. Hence, mGlu2 receptor activation can reduce gluta-
mate hyperfunction in diseases like schizophrenia and anxiety [4,5],
whereas mGlu2 receptor blockade can be beneﬁcial for glutamate hy-
pofunction in depression and impaired cognition [6,7].
A variety of glutamate-like ligands targeting the orthosteric binding
site in the VFT domain was developed including the reference agonist
LY354740 and antagonist LY341495 [8,9]. Until the recent disclosure
of the mGlu2 selective agonist LY2812223 [10], development of or-
thosteric ligands presented challenges for receptor subtype selectivity
and therefore discovery eﬀorts shifted to allosteric modulators that bind
in a less conserved pocket in the 7TM domain [11]. Allosteric mod-
ulators enhance or inhibit the potency and/or eﬃcacy of the en-
dogenous/orthosteric agonist with little or no intrinsic activity [12].
Two positive allosteric modulators (PAMs) have advanced into clinical
trials: AZD8529 [13,14] and JNJ-40411813/ADX71149 [15,16]. Re-
ference PAMs in the ﬁeld include BINA [17], JNJ-40068782 [18] and
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JNJ-46281222 [19]. A number of negative allosteric modulators
(NAMs) have been characterized in vivo, including a recent series of
Janssen, RO4491533 and decoglurant of which the latter has advanced
into clinical trials [7,20–22].
Over the last decade it has become increasingly clear that in vivo
eﬃcacy is not only depending on optimized in vitro aﬃnity and eﬃcacy
parameters, but also on optimized kinetics of both receptor binding and
activation [23]. The dissociation rate constant koﬀ and its derived
parameter residence time (RT=1/koﬀ) have received increasing at-
tention since the in vivo eﬃcacy of multiple marketed GPCR drugs was
shown to be related to long RT at the target, such as the long-acting M3
receptor antagonist tiotropium [24,25]. Although most kinetic studies
have emphasized dissociation rate constants, association rate constants
have also been described to be important for fast onset of drug action, a
high receptor occupancy and even a longer duration of action [26,27].
The importance of kon was further underscored for its potential in drug
safety by Sykes et al. (2017) who showed that extrapyramidal side ef-
fects induced by dopamine D2 receptor antagonists are linked to kon
rather than koﬀ as had been the general hypothesis so far [28].
We have recently shown the importance of kon and koﬀ for mGlu2
PAMs, where their aﬃnity was kon-driven and their koﬀ was linked to in
vivo eﬃcacy [29]. Except for this study, no previous studies have ex-
tensively focused on binding kinetics of mGlu2 ligands. Understanding
of binding kinetics may also be helpful in drug discovery of novel or-
thosteric mGlu2 ligands. Moreover, appreciating the kinetic binding
parameters of the endogenous agonist is important when designing
orthosteric ligands as they have to compete for the same binding site
[30]. Furthermore, determination of alterations of the kinetic para-
meters of the endogenous ligand induced by an allosteric modulator
will provide valuable mechanistic insights. Since kinetic binding para-
meters of the endogenous mGlu2 agonist glutamate have not been
quantiﬁed before we set up a kinetic radioligand binding assay to en-
able quantiﬁcation of kinetic parameters for orthosteric ligands. The
major mechanism of action of many allosteric modulators is to mod-
ulate endogenous agonist aﬃnity by aﬀecting its kinetic binding
parameters, as aﬃnity is determined by KD= koﬀ/kon. Therefore, ki-
netic binding experiments with orthosteric ligands were also performed
in the presence of a PAM or NAM. Additionally, we performed func-
tional assays, i.e. [35S]GTPγS binding assays measuring G protein ac-
tivation and a label-free biosensor assay that measures changes in cell
morphology representing a more integral cellular response. These
functional assays were used to further study the interplay between the
orthosteric and allosteric binding sites, and its eﬀect on the level of
functional eﬃcacy. Importantly, the cell morphology assay enabled
recording in real-time, thereby providing the opportunity to evaluate
functional receptor-induced responses over time in addition to the time-
dependent binding kinetics assays.
This work provides insights on the binding kinetics of orthosteric
ligands at the mGlu2 receptor and modulation thereof by PAMs or
NAMs. As such, it contributes to increased molecular understanding
which may strengthen future drug discovery projects focusing on the
development of both orthosteric ligands or allosteric modulators for the
mGlu2 receptor as well as for other GPCRs.
2. Materials and methods
2.1. Chemicals and reagents
LY354740, JNJ-46281222, JNJ-40068782, BINA, RO4491533, and
[3H]JNJ-46281222 were synthesized at Janssen Research and
Development. LY341495 was from Tocris BioScience (Bristol, UK). [3H]
LY341495 was obtained from American Radiolabeled Companies (St.
Louis, MO, USA) and [35S]GTPγS from PerkinElmer (Groningen, The
Netherlands). Dulbecco’s modiﬁed Eagle’s medium (DMEM), gluta-
mate, GDP and Glutamate-pyruvate transaminase (GPT) were from
Sigma Aldrich (St. Louis, MO, USA). Penicillin, streptomycin, L-Proline
and G418 were obtained from Duchefa Biochemie (Haarlem, The
Netherlands). Fetal calf serum (FCS) was from Biowest (Nuaillé,
France). CHO-K1 cells stably expressing the wildtype (WT) hmGlu2
receptor (CHO-K1_hmGlu2) were from Janssen Research and
Development. Other chemicals were from standard commercial sources.
2.2. Cell culture
CHO-K1_hmGlu2 cells were cultured in Dulbecco’s modiﬁed Eagle’s
medium (DMEM) supplemented with 10% (v/v) fetal calf serum,
200 IU·mL−1 penicillin, 200 µg·mL−1 streptomycin, 30.5 µg·mL−1 L-
proline and 400 µg·mL−1 G418 at 37 °C and 5% CO2. Cells were sub-
cultured twice every week at a ratio of 1:10.
2.3. Membrane preparation
Membrane preparation was performed as previously described [19].
2.4. Radioligand binding assays
2.4.1. [3H]LY341495 binding assays
Membranes were thawed and subsequently homogenized using an
Ultra Turrax homogenizer at 24,000 rpm (IKA-Werke GmbH & Co.KG,
Staufen, Germany). Assay buﬀer (50mM Tris-HCl pH 7.4, 2 mM CaCl2,
10mMMgCl2) was used to dilute the samples to a total reaction volume
of 100 µl containing 5 µg membrane protein and 4 nM [3H]LY341495.
Incubations were performed at 0 °C. Nonspeciﬁc binding was de-
termined using 1mM glutamate and DMSO concentrations were
≤0.25%.
Displacement experiments were carried out using radioligand and a
competing ligand at multiple concentrations. Samples were incubated
for 60min, after which receptor-bound radioactivity was determined.
Association experiments were performed by incubation of radi-
oligand in the absence or presence of allosteric modulator at 1 µM with
membrane aliquots. The amount of receptor-bound radioligand was
determined at diﬀerent time points up to 60min.
Dissociation experiments were carried out by a 60min pre-incuba-
tion of radioligand and membrane aliquots in the absence or presence
of allosteric modulator at 1 µM. The amount of receptor-bound radi-
oligand was determined after dissociation at diﬀerent time points up to
60min which was initiated by addition of 5 µl assay buﬀer containing
LY341495 (ﬁnal concentration 10 µM).
Competition association experiments were performed by incubation
of radioligand, competing ligand at its IC50 concentration in the ab-
sence or presence of allosteric modulator at 1 µM with membrane ali-
quots. The amount of receptor-bound radioligand was determined at
diﬀerent time points up to 60min.
For all assays, incubations were terminated by rapid ﬁltration over
GF/C ﬁlter plates (PerkinElmer) using a PerkinElmer 96w Filtermate
harvester. Subsequently ﬁlters were washed ﬁve times using ice-cold
wash buﬀer (50mM Tris-HCl pH 7.4). Filter-bound reactivity was de-
termined using liquid scintillation spectrometry on a Microbeta 24502
microplate counter (PerkinElmer).
2.4.2. [35S]GTPγS binding assays
Membrane homogenates (10 µg) were diluted in assay buﬀer
(50mM Tris-HCl pH 7.4, 100mM NaCl, 3 mM MgCl2) supplemented
with 5 µg saponin and 10 µM GDP to a total volume of 80 µl containing
increasing concentrations of ligand of interest in the absence or pre-
sence of a glutamate concentration equivalent to its EC80 value (60 µM),
if indicated. Basal and maximal receptor activity was determined in the
presence of only assay buﬀer or 1mM glutamate, respectively. After a
30min pre-incubation at 25 °C, 20 µl [35S]GTPγS (ﬁnal concentration
0.3 nM) was added. Reactions were stopped after 90min incubation at
25 °C. Filtration was performed and ﬁlter-bound radioactivity de-
termined as described under ‘[3H]LY341495 binding assays’ except that
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GF/B ﬁlter plates were used and the wash-buﬀer consisted of 50mM
TRIS-HCl and 5mM MgCl2.
2.5. Impedance-based morphology assays
Impedance-based morphology assays were performed using the real-
time cell analyser (RTCA) xCELLigence SP system (ACEA Biosciences,
San Diego, CA, USA) [31,32], as previously described [33]. The system
measures electrical impedance generated by adherence of cells to gold-
coated electrodes at the bottom of 96 wells PET E-plates (obtained from
Bioké, Leiden, the Netherlands). Changes in impedance (Z) are mea-
sured continuously and are displayed as Cell Index (CI), which is de-
ﬁned as (Zi− Z0) Ω/15Ω. Zi is the impedance at a given time and Z0 is
the baseline impedance measured at the start of the experiment in the
absence of cells. Baseline impedance was determined using 45 µl cul-
ture medium (as described under ‘cell culture’) per well in a 96 well E-
plate. 40,000 CHO-K1_hmGlu2 cells were added in a volume of 50 µl per
well. After resting at room temperature for 30min, the plate was
mounted in the recording station within a humidiﬁed 37 °C, 5% CO2
incubator. Impedance was measured every 15min overnight. 18 h after
cell seeding, wells were stimulated with increasing concentrations of
glutamate in the absence or presence of 1 µM PAM JNJ-46281222, re-
sulting in ﬁnal well volumes of 100 µl. DMSO concentrations were
0.025% and constant between wells.
2.6. Data analysis
Data analyses were performed using Prism 7.00 (GraphPad soft-
ware, San Diego, CA, USA). pIC50 values in radioligand displacement
assays were obtained by non-linear regression curve ﬁtting into a sig-
moidal concentration-response curve using the equation:
Y=Bottom+ (Top-Bottom)/(1+10^(X-LogIC50)). pKi values were
obtained from pIC50 values using the Cheng-Prusoﬀ equation [34].
Dissociation rate constant koﬀ was obtained using an exponential decay
analysis of radioligand binding. Association rate constant kon was de-
termined using the equation kon=(kobs− koﬀ)/[L], in which L is the
concentration of radioligand and kobs was determined using an ex-
ponential association analysis of radioligand binding.
Association and dissociation rate constants for unlabelled mGlu2
PAMs were determined by nonlinear regression analysis of competition
association data as described by Motulsky and Mahan [35].
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pEC50 and pIC50 values in the [35S]GTPγS binding assays were de-
termined using non-linear regression curve ﬁtting into a sigmoidal
concentration–response curve using the equation: Y=Bottom+ (Top-
Bottom)/(1+10^(LogEC50-X)*Hill Slope)). The same equation was
used to determine pEC50 values from the impedance-based morphology
assay. Baseline-corrected ΔCI levels at indicated time points were used
to obtain these concentration-response curves. Data are shown as
mean ± SEM of at least three individual experiments performed in
duplicate. Statistical analyses were performed as indicated. If p-values
were below 0.05, observed diﬀerences were considered statistically
signiﬁcant.
3. Results
3.1. Aﬃnity of orthosteric ligands in the absence or presence of allosteric
modulators
The aﬃnities of orthosteric agonists glutamate and LY354740 and
antagonist LY341495 were determined by [3H]LY341495 displacement
assays in the absence and presence of PAMs JNJ-46281222 (1 µM),
BINA (10 µM) and JNJ-40068782 (1 µM) or NAM RO4491533 (1 µM)
(Fig. 1A–C, Table 1). The aﬃnity of both the endogenous agonist glu-
tamate and the synthetic agonist LY354740 was signiﬁcantly increased
in the presence of all PAMs. Speciﬁcally, in presence of JNJ-46281222,
glutamate aﬃnity was increased by 7-fold (pKi 4.52 ± 0.04 to
5.40 ± 0.08 in the absence and presence of JNJ-46281222, respec-
tively), while the aﬃnity of LY354740 was increased by 5-fold (pKi
Fig. 1. Aﬃnity of orthosteric ligands and the eﬀect of allosteric modulators thereon. [3H]LY341495 displacement by orthosteric agonists A) glutamate and B)
LY354740 and antagonist C) LY341495 in the absence or presence of PAMs or NAM. D) [3H]LY341495 binding in the presence of increasing concentrations of the
PAM JNJ-46281222 or NAM RO4491533. Ki values obtained from these graphs are described in Table 1. Data represent the mean ± SEM of three individual
experiments performed in duplicate. If not shown, error bars are within the symbol.
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6.79 ± 0.01 to 7.51 ± 0.15 in the absence and presence of JNJ-
46281222, respectively). The aﬃnity of antagonist LY341495 (pKi
8.39 ± 0.09) was not aﬀected by any of the PAMs. The presence of
1 µM NAM RO4491533 did not aﬀect the aﬃnity of glutamate,
LY354740 or LY341495, which shows that the presence of the NAM
does not inhibit the orthosteric agonists and antagonist from binding to
the receptor. Since JNJ-46281222 induced the highest shift in agonist
aﬃnity it was used as representative PAM for further experimentation,
along with RO4491533 as a representative NAM. Of note, both JNJ-
46281222 and RO4491533 were not able to displace the radiolabelled
orthosteric antagonist [3H]LY341495 by themselves (Fig. 1D), which
indicates that they bind to an allosteric site at the mGlu2 receptor.
3.2. Binding kinetics of orthosteric ligands
We set-up radioligand binding assays allowing the determination of
binding kinetics of orthosteric ligands in the absence or presence of
allosteric modulators. The kinetic binding parameters kon and koﬀ of
[3H]LY341495 were determined using classical (direct) association and
dissociation assays (Fig. 2A, Table 2). [3H]LY341495 associated rapidly
to the mGlu2 receptor, where complete association was reached within
5min, resulting in a kobs value of 0.015 ± 0.0007 s−1. Dissociation
induced by 10 µM unlabelled LY341495 yielded a koﬀ value of
0.0066 ± 0.0001 s−1. Based on these kobs and koﬀ values and the
concentration of the radioligand used, kon was calculated as
2.2 ± 0.17× 106M−1 s−1. To obtain kinetic binding parameters for
unlabelled orthosteric ligands, a competition association assay was
performed (Fig. 2B–D). The assay was ﬁrst validated using unlabelled
LY341495, for which kon and koﬀ values were comparable to those
obtained in the classical association and dissociation assays (Table 3).
Subsequently, the kinetic binding parameters of glutamate and
LY354740 were assessed (Fig. 2C,D; Table 3). Compared to LY341495,
glutamate had a signiﬁcantly lower kon value of
1.6 ± 0.3×103M−1 s−1 and a faster dissociation rate (koﬀ
0.036 ± 0.008 s−1). Interestingly, LY354740 had a koﬀ value similar to
that of glutamate, but a 40-fold higher kon value (koﬀ
0.045 ± 0.010min−1 and kon 7.1 ± 2.9×104M−1 s−1, respec-
tively). Of note, the KD values, i.e. calculated based on their kon and koﬀ
values, for glutamate, LY35470 and LY341495, were in good agreement
with the Ki values obtained from equilibrium displacement assays
(compare Tables 1 and 3).
3.3. The eﬀect of allosteric modulators on the binding kinetics of orthosteric
ligands
The kinetic binding parameters kon and koﬀ of glutamate, LY354740
and LY341495 were determined in the presence of PAM JNJ-46281222
or NAM RO4491533 at 1 µM (Fig. 2B–D; Tables 2 and 3). The kon value
for glutamate in the presence of 1 µM JNJ-46281222 was slightly but
not signiﬁcantly increased to 2.4 ± 0.18× 103M−1 s−1 compared to
its value obtained in the absence of PAM. The koﬀ value on the other
hand was signiﬁcantly decreased by 3-fold to 0.012 ± 0.001min−1.
Table 1
Aﬃnity (pKi) of orthosteric ligands in the absence and presence of allosteric
modulators determined in [3H]LY341495 displacement assays.
Glutamate LY354740 LY341495
Vehicle 4.52 ± 0.04 6.79 ± 0.01 8.39 ± 0.09
+ 1 µM JNJ-46281222 5.40 ± 0.08*** 7.51 ± 0.15* 8.54 ± 0.02
+ 10 µM BINA 5.30 ± 0.09*** 7.38 ± 0.03* 8.57 ± 0.08
+ 1 µM JNJ-40068782 5.23 ± 0.04*** 7.43 ± 0.19* 8.59 ± 0.05
+ 1 µM RO4491533 4.56 ± 0.03 6.93 ± 0.15 8.65 ± 0.10
Values represent the mean ± SEM of three individual experiments performed
in duplicate. Statistical analyses were performed using a one-way ANOVA with
Dunnett’s post-test. * < 0.05, *** < 0.001.
Fig. 2. Binding kinetics of orthosteric ligands and the eﬀects of allosteric modulators thereon. A) Association and dissociation kinetics of 4 nM [3H]LY341495 at the
mGlu2 receptor at 0 °C. Competition association of the agonists B) glutamate and C) LY354740 and D) antagonist LY341495 in the absence or presence of PAM JNJ-
46281222 or NAM RO4491533 at 1 µM. Parameters obtained from these graphs are described in Tables 2 and 3. Data represent the mean ± SEM of at least three
individual experiments performed in duplicate.
Table 2
Kinetic binding parameters (kon, koﬀ) of antagonist LY341495 in the absence or
presence of JNJ-46281222 (PAM) or RO4491533 (NAM), determined by direct
[3H]LY341495 association and dissociation assays.
Assay KD (nM)a kon (M−1 s−1) koﬀ (s−1)
LY341495 2.9 ± 0.23 (2.2 ± 0.17)× 106 0.0066 ± 0.0001
+ 1 µM PAM 2.9 ± 0.24 (2.2 ± 0.67)× 106 0.0063 ± 0.0003
+ 1 µM NAM 3.2 ± 0.17 (2.1 ± 0.65)× 106 0.0068 ± 0.0002
a Kinetic KD values, deﬁned by KD= koﬀ/kon. Values represent the
mean ± SEM of three individual experiments performed in duplicate.
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Together, this resulted in an approximately 5-fold increased ‘kinetic’
aﬃnity (KD) for glutamate from 23 ± 6.9 to 4.7 ± 0.6 µM, which was
also observed in the equilibrium displacement assays (Ki values, com-
pare Tables 1 and 3). In the presence of 1 µM RO4491533, the kon value
of glutamate was signiﬁcantly increased by 3-fold to
5.2 ± 0.37×103M−1 s−1, while the koﬀ value was also signiﬁcantly
increased by 3-fold to 0.12 ± 0.009 s−1. As a result, the kinetic KD
value did not change compared to glutamate in the absence of NAM
(24 ± 2.4 µM and 23 ± 6.9 µM in absence or presence of NAM, re-
spectively).
The kon value of LY354740 was left unchanged in the presence of
1 µM JNJ-46281222 (7.3 ± 0.56× 104M−1 s−1), whereas the koﬀ
value was decreased by 3-fold to 0.013 ± 0.001 s−1. Together this led
to an increased kinetic KD value of 180 ± 20 nM of the agonist
LY354740 in the presence of PAM JNJ-46281222. Interestingly, in
contrast to glutamate, no signiﬁcant shifts in kon or koﬀ values were seen
for the agonist LY354740 in the presence of 1 µM RO4491533, and
therefore the kinetic KD was also unaﬀected (630 ± 290 and
550 ± 200 nM in absence or presence of NAM, respectively).
Lastly, both kon and koﬀ values of the antagonist LY341495 were not
signiﬁcantly altered by the presence of PAM or NAM. This was the case
for both the direct [3H]LY341495 association and dissociation assays
(Fig. 2A, Table 2), as well as for the completion association assays
(Fig. 2D, Table 3). Hence, KD values were similar to those obtained in
the absence of allosteric modulator.
3.4. Potency and eﬃcacy of orthosteric ligands, eﬀects of allosteric
modulators on LY354740 potency and eﬃcacy
To evaluate the eﬀects of JNJ-46281222 and RO4491533 on the
functional responses induced by orthosteric ligands, a functional
[35S]GTPγS binding assay was used that measures compound-induced G
protein activation. Firstly, concentration-response curves of the ago-
nists glutamate and LY354740 were made (Fig. 3A), which led to pEC50
values of 4.95 ± 0.01 and 6.94 ± 0.04, respectively. The maximum
level of [35S]GTPγS binding induced by the synthetic agonist LY354740
was 83.5 ± 1.2% compared to the maximum response induced by the
endogenous agonist glutamate (100% at 1mM) (Table 4). The potency
of the antagonist LY341495 was determined in the presence of an EC80
concentration of glutamate (60 µM). LY341495 inhibited glutamate-
induced [35S]GTPγS binding with a pIC50 value of 7.40 ± 0.04
(Fig. 3A). Secondly, the eﬀects of increasing concentrations of JNJ-
46281222 or RO4491533 on the concentration-response curves of
LY354740 were assessed (Fig. 3B, Table 4). Increasing concentrations of
the PAM JNJ-46281222 induced a concentration-dependent increase in
Emax up to approximately 220% at a concentration of 30 nM or higher.
Moreover, the potency of LY354740 was increased signiﬁcantly from
6.94 ± 0.04 in the absence of PAM to 7.69 ± 0.07 in the presence of
100 nM JNJ-46281222. In contrast, when LY35470 was treated with
Table 3
Kinetic binding parameters (kon, koﬀ) for agonists glutamate and LY354740 and antagonist LY341495 in the absence or presence of JNJ-46281222 (PAM) or
RO4491533 (NAM) obtained from competition association assays using [3H]LY341495.
KD (nM)a (pKD) kon (M−1 s−1) koﬀ (s−1)
Glutamate 23000 ± 6900 (4.65) (1.6 ± 0.3)× 103 0.036 ± 0.008
+ 1 µM PAM 4700 ± 600* (5.33) (2.4 ± 0.18)× 103 0.012 ± 0.001*
+ 1 µM NAM 23500 ± 2400 (4.63) (5.2 ± 0.37)× 103*** 0.12 ± 0.009***
LY354740 630 ± 290 (6.20) (7.1 ± 2.9)× 104 0.045 ± 0.010
+ 1 µM PAM 180 ± 20 (6.74) (7.3 ± 0.56)× 104 0.013 ± 0.001*
+ 1 µM NAM 550 ± 200 (6.26) (8.5 ± 2.1)× 104 0.047 ± 0.013
LY341495 3.5 ± 0.46 (8.45) (2.4 ± 0.18)× 106 0.0087 ± 0.0009
+ 1 µM PAM 2.8 ± 0.40 (8.56) (3.5 ± 0.46)× 106 0.0096 ± 0.0006
+ 1 µM NAM 3.4 ± 1.2 (8.46) (3.9 ± 0.93)× 106 0.013 ± 0.003
a Kinetic KD values, deﬁned by KD= koﬀ/kon. Values represent the mean ± SEM of three individual experiments performed in duplicate. Statistical analyses were
performed using a one-way ANOVA with Dunnett’s post-test. * < 0.05, ** < 0.01, *** < 0.001.
Fig. 3. Intrinsic agonist potency and eﬃcacy and the eﬀect of allosteric modulators thereon. A) Concentration-response curves of glutamate- and LY354740-induced
[35S]GTPγS binding and concentration-response curve of inhibition of glutamate induced (EC80: 60 µM) [35S]GTPγS binding by LY341495. Eﬀects of increasing
concentrations of B) JNJ-46281222 and C) RO4491533 on concentration-response curves of LY354740 in the [35S]GTPγS binding assay. Parameters obtained from
these graphs are described in Table 4. Data are expressed as the percentage of maximal response induced by 1mM glutamate (100%) and represent the mean ± SEM
of three individual experiments performed in duplicate. If not shown, error bars are within the symbol.
Table 4
Eﬀect of allosteric modulators JNJ-46281222 (PAM) and RO4491533 (NAM)
on LY354740-induced [35S]GTPγS binding.
LY354740
pEC50 Emax (%)a
LY354740 6.94 ± 0.04 83.5 ± 1.2
+ 1 nM JNJ-46281222 7.04 ± 0.10 117 ± 4.2
+ 3 nM JNJ-46281222 7.14 ± 0.08 154 ± 11**
+ 10 nM JNJ-46281222 7.35 ± 0.10** 178 ± 16***
+ 30 nM JNJ-46281222 7.50 ± 0.07**** 215 ± 22****
+ 100 nM JNJ-46281222 7.69 ± 0.07**** 222 ± 22****
+ 1 nM RO4491533 6.91 ± 0.07 74.5 ± 1.3**
+ 3 nM RO4491533 6.87 ± 0.11 55.5 ± 2.5****
+ 10 nM RO4491533 6.69 ± 0.05 30.0 ± 1.6****
a Expressed as percentage of [35S]GTPγS binding induced by 1mM gluta-
mate (set at 100%). Values represent the mean ± SEM of three individual
experiments performed in duplicate. Statistical analyses were performed using a
one-way ANOVA with Dunnett’s post-test. ** < 0.01, *** < 0.001,
**** < 0.0001.
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increasing concentrations of the NAM RO4491533, the Emax values of
the concentration-response curves were reduced concentration-depen-
dently. At a concentration of 30 nM RO4491533 or higher, LY354740-
induced [35S]GTPγS binding was completely abolished (Fig. 3C,
Table 4). Interestingly, the potency of LY354740 did not change sig-
niﬁcantly in the presence of increasing NAM concentrations.
3.5. Eﬀect of PAM JNJ-46281222 on duration of glutamate-induced
cellular response using an impedance-based morphology assay
To gain further insights in the functional impact of allosteric mod-
ulation, receptor activation by glutamate was evaluated using an im-
pedance-based morphology assay (i.e. xCELLigence). This method can
record receptor-speciﬁc cellular responses in real-time, and thus com-
pound-induced changes in cellular dynamics can be measured over
time. Glutamate-induced responses were recorded at increasing con-
centrations in the absence and presence of 1 µM PAM JNJ-46281222
resulting in a concentration-dependent increase in impedance, depicted
as Cell Index (Fig. 4A,B). Similar to the [35S]GTPγS assay, the glutamate
potency was signiﬁcantly (p < 0.05, student’s t-test) increased from
pEC50 5.27 ± 0.19 to 5.99 ± 0.12 in the absence and presence of
PAM, respectively. Furthermore, the PAM-induced shift in potency for
glutamate in the morphology assay was comparable to the shift for
LY354740 in the [35S]GTPγS assay (Table 4). Interestingly, the duration
of the glutamate-induced response in the presence of PAM was also
increased from approximately 45 to over 60min. To further evaluate
this eﬀect, concentration-response curves of glutamate in the absence
and presence of the PAM were obtained at two diﬀerent time points
after stimulation, i.e. 15 and 45min (Fig. 4C,D). Comparison of these
concentration-response curves yielded a 2-fold decrease in eﬃcacy for
the curve from the later time point (Fig. 4C), congruent with the almost
loss of glutamate signal in the absence of PAM at 45min (Fig. 4A). In
contrast, the glutamate eﬃcacy in the presence of PAM did not change
signiﬁcantly, when comparing the concentration-response curves of 15
and 45min after stimulation. This is in line with the observation that
the duration of the glutamate-induced response is prolonged by the
PAM to approximately 60min, and thus a decrease in cellular im-
pedance was not yet observed at 45min (Fig. 4B). Of note, when
comparing the potencies for each condition, i.e. glutamate in the ab-
sence or presence of PAM, these were not signiﬁcantly diﬀerent at the
two time points selected (Fig. 4C,D).
3.6. Correlations and kinetic map
To compare the parameters obtained from the diﬀerent radioligand
binding assays, correlation plots were made (Fig. 5A–C). As mentioned
above, the aﬃnity values obtained from [3H]LY341495 equilibrium
displacement assays (Ki) and [3H]LY341495 competition association
assays (KD) were in very good agreement, as exempliﬁed by a high
linear correlation (Fig. 5A, R2=0.95), further corroborating the ro-
bustness of the latter assay. A signiﬁcant correlation was also found
between aﬃnity (Ki) and association rate constants (kon) (Fig. 5B,
R2= 0.99). Such a correlation, however, was not found between aﬃ-
nity (Ki) and dissociation rate constants (koﬀ) (Fig. 5C, R2= 0.29), in-
dicating that aﬃnities of these orthosteric ligands are predominantly
kon-driven.
A kinetic map was made, to further compare the kinetic and aﬃnity
parameters (Fig. 5D). In this map kon (x-axis), koﬀ (y-axis) and KD (di-
agonal lines) values were plotted. kon and KD values ranged over more
than three orders of magnitude, whereas koﬀ values were only spread
within a single order of magnitude and therefore appeared at a similar
horizontal level in the kinetic map (Fig. 5D).
As shown in Table 3, kon and koﬀ values of glutamate were aﬀected
by both PAM and NAM, which was exempliﬁed in the kinetic map by a
spread in symbols. Speciﬁcally, in the presence of PAM, the koﬀ of
glutamate was decreased by 3-fold. In the presence of NAM both kon and
koﬀ were increased 3-fold resulting in the same aﬃnity as illustrated by
a diagonal shift of the NAM symbol, i.e. a shift along the line of similar
KD. In the presence of PAM, the koﬀ of LY354740 was similarly aﬀected
compared to glutamate, i.e. in both cases this resulted in a downward
shift on the kinetic map, whereas in the presence of NAM no signiﬁcant
shifts were observed, resulting in nearly overlapping symbols. Since the
kon and koﬀ values of LY34195 were not aﬀected by PAM or NAM all
three symbols are overlapping in the kinetic map.
To compare the functional potency of agonists in the absence or
presence of PAM to the kinetic parameters kon and koﬀ further corre-
lation plots were made (Fig. 5E–G). Firstly, the potencies (EC50) ob-
tained in [35S]GTPγS assays of agonists glutamate and LY354740 were
shown to be strongly correlated (Fig. 5E, R2=0.99) to the aﬃnity
obtained from competition association assays (KD), showing that po-
tencies are driven by the agonist binding aﬃnities although the abso-
lute values diﬀered by approximately one log unit. As the aﬃnities
were shown to be correlated to on-rates, a correlation was also found
Fig. 4. Eﬀect of PAM JNJ-46281222 on the duration
of glutamate-induced signalling, as determined by
an impedance-based morphology assay. A,B) 18 h
after seeding, CHO-K1_hmGlu2 cells (40,000 cells/
well) were stimulated by increasing concentrations
of the agonist glutamate in absence (A) or presence
of 1 µM of the PAM JNJ-46281222 (B). Medium
with 0.025% DMSO was used as vehicle control.
DMSO concentrations were 0.025% in all cases. A
representative example is shown of a baseline-cor-
rected response, the so-called Δ cell index (ΔCI),
which was repeated at least three times in duplicate.
C,D) Concentration-response curves were obtained
from the ΔCI values at 15 or 45min after stimula-
tion. pEC50 values are mentioned in the results sec-
tion. xCELLigence traces (A, B) are from a re-
presentative experiment. Curves (C, D) represent
mean ± SEM of at least three individual experi-
ments performed in duplicate.
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between agonist potencies and kon values (Fig. 5F, R2=0.84), showing
that a high agonist potency is obtained from a high on-rate. No corre-
lation was found between agonist potency and dissociation rate con-
stant (koﬀ) (Fig. 5G, R2= 0.28). However, in the presence of PAM the
agonist koﬀ was decreased for both glutamate and LY354740, which
then was the driver for an increased agonist potency, as was also ob-
served for agonist aﬃnity in the presence of PAM.
4. Discussion
Traditionally, aﬃnity and potency are the main parameters studied
in in vitro drug discovery. In addition, a ligand’s target binding kinetic
parameters are nowadays commonly appreciated as valuable informa-
tion for the early phases of drug discovery [25]. For the development of
novel and eﬀective orthosteric mGlu2 ligands it is valuable to know
their kinetic binding parameters, but also to understand how these re-
late to the binding kinetics of the endogenous agonist glutamate [30].
Moreover, a variety of high aﬃnity and selective PAMs and NAMs have
been developed that modulate glutamate potency, eﬃcacy and/or af-
ﬁnity. As for orthosteric ligands, it is equally useful to know the al-
losteric modulator’s binding kinetics [29]. Likewise it is also relevant to
know how a modulator aﬀects the kinetic binding parameters of the
endogenous ligand glutamate. Hence, in the present study we aimed to
increase the understanding of binding kinetics of orthosteric mGlu2 li-
gands both on their own and upon modulation by an allosteric ligand.
The orthosteric ligands used in this study were the endogenous
agonist glutamate and reference orthosteric ligands LY354740 (agonist)
and LY341495 (antagonist). Radioligand displacement experiments
Fig. 5. Correlations between aﬃnity, potency and kinetic parameters. (A,B,C) Correlation between aﬃnity of glutamate (green), LY354740 (blue) and LY341495
(red) determined in [3H]LY341495 equilibrium displacement assays (Ki) and aﬃnity determined based on kinetic parameters kon and koﬀ obtained from [3H]
LY341495 competition association assays (KD) (A); aﬃnity (Ki) and association rate constant (kon) (B); aﬃnity (Ki) and dissociation rate constant (koﬀ) (C). D) Kinetic
map with the association rate constant (kon) plotted on the x-axis and the dissociation rate constant (koﬀ) on the y-axis. Identical aﬃnity (KD) values may result from
diﬀerent combinations of kon and koﬀ (KD= koﬀ/kon, diagonal dashed lines). E,F,G) Correlation between potency of glutamate and LY354740 determined in
[35S]GPTγS assays (EC50) and aﬃnity determined based on kinetic parameters kon and koﬀ obtained from [3H]LY341495 competition association assays (KD) (E). The
EC50 of glutamate in the presence of 1 µM PAM is from [19]; potency (EC50) and association rate constant (kon) (F); potency (EC50) and dissociation rate constant (koﬀ)
(G). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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(Fig. 1, Table 1) showed that these ligands bind the same orthosteric
binding site, which is in line with previous observations [36,37]. The
kinetic parameters kon and koﬀ of glutamate were quantiﬁed for the ﬁrst
time, using competition association experiments. To allow the set-up of
this assay kinetic [3H]LY341495 binding experiments were performed
which showed that this ligand associates to its binding site within four
minutes and dissociates in approximately ten minutes (Fig. 2A). For the
set-up of the competition association assay, the association and dis-
sociation of the radioligand should ideally be slower allowing more
data points on the steep part of the curves [38]. This is often achieved
by a temperature reduction. However, in these assays the temperature
could not be lowered, since it had to be set at 0 °C already to allow
quantiﬁcation of kinetic measurements using this commercially avail-
able radioligand. Still we could produce robust data between the dif-
ferent binding assays indicating their validity. To obtain values for kon
and koﬀ of unlabelled ligands in the absence and presence of allosteric
modulators, the Motulsky and Mahan model was used [35,38]. This
model requires input for the values of kon and koﬀ (k1 and k2 in the
model) of the labelled radioligand (i.e. [3H]LY341495). Importantly,
these values should remain constant throughout the experiments, as
was the case here for [3H]LY341495 which provided similar values for
kon and koﬀ both in the absence and presence of allosteric modulators
(Table 2). Due to the nature of the radioligand (i.e. fast receptor asso-
ciation) there is not much resolution in the association phase of the
curves, making it diﬃcult to observe diﬀerences in the rates by eye.
However, by analysis of the data with the Motulsky and Mahan model
we were able to obtain robust binding kinetic parameters between
diﬀerent experiments.
We found that glutamate dissociation (0.036 s−1, Table 3) is fast in
comparison to the series of mGlu2 PAMs we studied before, which
dissociate on a minute-range at 28 °C (koﬀ values between 0.00033 and
0.0040 s−1), which would be even slower at 0 °C [29]. The observation
of fast glutamate binding kinetics is in line with studies using FRET
sensors that found mGlu1 receptor conformational changes upon glu-
tamate binding within seconds [39,40]. Fast receptor dissociation of
glutamate relates to its physiological role as a neurotransmitter, where
short bursts of glutamate at high concentrations are released into the
synapse where it should evoke its function during that burst only [3].
Similarly, fast oﬀ-rates were obtained for other endogenous neuro-
transmitters as exempliﬁed by 2-AG and anandamide on the CB2 re-
ceptor (koﬀ=0.053 s−1 and 0.012 s−1 at 25 °C, respectively) [41] and
acetylcholine on the M3 receptor (koﬀ=0.093 s−1 at 37 °C) [42].
Comparison of these values is troublesome, since for practical reasons
experiments were performed at diﬀerent temperatures. Still, they all
share oﬀ-rates on the second to minute scale, indicating fast receptor
dissociation particularly when comparing to synthetic ligands at the
same receptors [41,42].
It is generally acknowledged that allosteric modulators may change
the aﬃnity and/or potency of agonists by modulating their kon and/or
koﬀ values [43]. Generally this has been determined by radioligand
dissociation experiments in the presence of allosteric modulators that
enable quantiﬁcation of modulated oﬀ-rates [44]. Limitations of such
assays are that it is impossible to detect eﬀects on a radioligand’s on-
rate and that the orthosteric/endogenous ligand of interest needs to be
radiolabelled. This is not suitable for most endogenous agonists in-
cluding glutamate due to a too low target aﬃnity, or too high non-
speciﬁc binding. Therefore, we used the competition association assay
for quantiﬁcation of both kon and koﬀ values of unlabelled orthosteric
ligands in the absence or presence of PAM or NAM, as was recently
published for an adenosine A1 receptor PAM [38]. The presence of PAM
JNJ-46281222 at 1 µM signiﬁcantly reduced the koﬀ of glutamate and
LY354740, resulting in an increased aﬃnity for both these agonists.
This was in line with the results from the radioligand displacement
assay (Table 1) and can be considered a typical PAM eﬀect [43]. A
similar eﬀect was also seen in the functional [35S]GTPγS binding assay
where the potency of LY354740 was increased by the PAM JNJ-
46281222 by almost 6-fold and its eﬃcacy was more than doubled in
line with earlier results using glutamate [19]. Furthermore, a decreased
koﬀ, i.e. increased residence time, for glutamate in the presence of 1 µM
PAM JNJ-46281222 results in a prolonged receptor occupancy, which
correlated to a prolonged cellular response in the morphology assay
(Fig. 4). This functional assay is performed on whole cells under phy-
siologically more relevant conditions (i.e. in culture medium, at 37 °C,
in a CO2 incubator) and is therefore considered to be more translational
than classical functional assays [31,32].
Furthermore, the assay can be performed in real-time, which en-
abled translation from kinetic binding parameters towards functional
eﬃcacy over time. Previous studies have also used this assay to study
the link between receptor binding kinetics, functional activation ki-
netics and duration of signalling for agonist-induced responses on the
dopamine D2 and neurokinin 1 receptors [45,46]. Of note, we have
previously shown that culture medium contains 100 µM endogenous
glutamate [47], and therefore the enzyme glutamate-pyruvate transa-
minase (GPT) is often used to reduce this level. In the current study we
were interested in the eﬀect of a PAM on glutamate-responses, as this is
the endogenous ligand and thus most relevant for PAM drug discovery.
Therefore, GPT could not be used as this would deplete exogenous
glutamate in addition to endogenous glutamate.
The NAM RO4491533 at 1 µM positively modulated both kon and
koﬀ of glutamate (Table 3), resulting in an unchanged aﬃnity. Of note,
these eﬀects on glutamate kinetics cannot be observed in the classical
radioligand displacement assays at equilibrium conditions, and would
therefore be missed (Table 1). On the other hand, RO4491533 was not
able to change kon and koﬀ of LY354740, which shows that the eﬀects of
this NAM on binding kinetics of agonists were probe-dependent [12].
This ﬁnding highlights the importance of using endogenous agonists in
studies of allosteric modulation, since results on other (synthetic)
agonists may provide diﬀerent conclusions as a result of probe-de-
pendency. The observation that a high 1 µM concentration of NAM
RO4491533 did not modulate the aﬃnity of both agonists indicated
that these ligands still bind the orthosteric binding site in the presence
of this NAM, which is therefore behaving as a silent or neutral allosteric
ligand (NAL) concerning orthosteric ligand binding [11]. On the con-
trary, RO4491533 displayed a strong negative cooperativity in the
functional [35S]GTPγS binding assay as it concentration-dependently
decreased the eﬃcacy of the agonist LY354740 without changing its
potency, eventually resulting in abolished LY354740 eﬃcacy (Fig. 3;
Table 4), similar to its eﬀects on glutamate activity [22]. This mode of
negative allosteric modulation, i.e. only aﬀecting eﬃcacy, has been
found across the class C GPCR family. NAMs such as CPCCOEt (mGlu1)
and MPEP (mGlu5) also abolished agonist eﬃcacy without modulation
of binding aﬃnity [48,49]. The absence of cooperativity between
LY341495 and both PAM and NAM was further illustrated by the ob-
servation that kon and koﬀ of LY341495 were not aﬀected by any al-
losteric modulator (Table 3).
The kinetic parameters of glutamate, LY354740 and LY341495 were
most diﬀerent in kon, ranging over more than three orders of magnitude
(from 1.6 ± 0.3× 103 to 2.4 ± 0.18× 106M−1 min−1) as did their
aﬃnity values, whereas koﬀ values were all within a 6-fold range (from
0.0087 ± 0.0009 to 0.045 ± 0.010). The correlation plots Fig. 5 show
that kon is strongly correlated to the agonist aﬃnity and potency, which
indicates that target engagement of orthosteric mGlu2 ligands is kon-
driven. Recent simulation studies have emphasized the role of high kon
values for receptor occupancy and drug dosing [26,27]. A mechanism
responsible for these eﬀects may be receptor rebinding, which is de-
scribed as the binding of newly dissociated ligand from the local en-
vironment of the receptor [50]. The interstitial localization of the
mGlu2 receptor may result in more rebinding due to less diﬀusion and
therefore higher local concentrations. However, rebinding to the mGlu2
receptor seems less likely for glutamate due to its low kon value (both in
the absence and presence of a PAM – Table 3) and the active lowering of
local glutamate concentrations by glutamate transporters expressed on
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the neuronal cell membrane and surrounding glial cells [51]. In con-
trast, rebinding may play a more prominent role in binding of synthetic
ligands which have higher kon values and are not actively transported
away from their site of action, resulting in higher in vivo receptor oc-
cupancy [50]. The plots in Fig. 5 furthermore showed that whereas
between diﬀerent PAMs a higher aﬃnity is obtained from a higher kon,
the higher agonist aﬃnity and potency obtained in the presence of a
PAM results from a lowered koﬀ value as has been shown to be a
common mechanism of action for many PAMs at diﬀerent GPCRs [43].
As shown in Fig. 5, koﬀ is not correlated to both aﬃnity and potency.
This is similar to our recent work on mGlu2 PAMs and this may
therefore be a receptor-speciﬁc property [29]. Furthermore, this earlier
study provided a ﬁrst indication that PAM koﬀ values may be correlated
to in vivo eﬃcacy, as measured by eﬀects on sleep-wake architecture in
rats, more speciﬁcally suppression of Rapid Eye Movement (REM) sleep
[52]. In the light of the current observation that the presence of a PAM
prolonged glutamate-induced cellular responses by decreasing its koﬀ, it
may be speculated that koﬀ values of both the PAM and the endogenous
agonist are important for the duration of action and thus also for in vivo
eﬃcacy. As such, this information is valuable for the design of novel
orthosteric and allosteric ligands in early drug discovery.
In conclusion, the set-up of a competition association radioligand
binding assay enabled quantiﬁcation of the parameters of binding ki-
netics for glutamate for the ﬁrst time. koﬀ values of the orthosteric li-
gands were within a single order of magnitude, whereas kon values were
spread over more than three orders of magnitude and were strongly
correlated to aﬃnity, indicating that mGlu2 target engagement is driven
by kon rather than koﬀ. Binding kinetics of agonists were modulated by
the PAM, showing a decrease in koﬀ of both agonists and a prolonged
functional response for glutamate. The NAM altered kon and koﬀ of
glutamate without changing glutamate’s aﬃnity, but did not induce
such alterations for agonist LY354740, which indicates probe-de-
pendency. These results show that aﬃnity or potency-only optimization
of orthosteric ligands will result in a high kon value but not necessarily
optimized koﬀ values, which is essential for optimal in vivo eﬃcacy, as
shown by previous studies. Together, this work contributes to an in-
creased understanding of the molecular processes that underlie the
mechanism of GPCR allosteric modulation, speciﬁcally how allosteric
modulators aﬀect the kinetic parameters of the endogenous agonist.
Therefore, this study further emphasizes the need for evaluation of
binding kinetics during drug discovery of both orthosteric and allosteric
drug candidates for the mGlu2 receptor as well as for other GPCRs.
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